Pancreatic neuroendocrine tumors in patients with tuberous sclerosis: a multicenter study and systematic review
Authors:
- Kalyan Mansukhbhai ShekhdaKSKalyan Mansukhbhai Shekhda
- John HowatJHJohn Howat
- Yujia GaoYGYujia Gao
- Anat Bel-AngeABAnat Bel-Ange
- Simona Grozinsky-GlasbergSGSimona Grozinsky-Glasberg
- Gregory KaltsasGregory Kaltsas
- Kai Man Alexander HoKHKai Man Alexander Ho
- Aimee R HayesAHAimee R Hayes
- Dalvinder MandairDMDalvinder Mandair
- Christos ToumpanakisChristos Toumpanakis
- Efthimia KarraEKEfthimia Karra
Open Access
- 1 August 2026
- journal article
- review article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (9)
Abstract
Introduction: Pancreatic neuroendocrine tumors (pNETs) are a recognized feature of tuberous sclerosis complex (TSC). The current evidence suggests that pNETs occurring in TSC may exhibit a different clinical course from sporadic cases, but their natural history remains poorly characterized. Objective: This study aimed to characterize the demographics, clinical presentation, management, and long-term outcomes of TSC-associated-pNETs and to propose possible guidelines for surveillance and management. Materials and Methods: We conducted a multicenter retrospective review of TSC-pNET patients from 6 UK TSC specialist clinics and from 3 NET referral centers, from 2008 to 2024. Data on demographics, tumor characteristics, management, and outcomes, were collected. A systematic review of the literature from 2009 to 2026 on TSC-pNETs was also performed. Results: We identified a total of 26 consecutive cases with the TSC-pNET-association in our cohort: 21 cases of pNETs from TSC specialist clinics (1.1% of the population), and 5 cases of TSC-pNETs from the NET referral centers (0.25% of the population). An additional 80 cases were identified from the published literature. We observed a wide spectrum of clinical phenotypes, with the majority being nonfunctioning pNETs (n = 24; 92%), whereas 2 patients were diagnosed with glucagonomas. Surgical intervention was the mainstay initial treatment, the indication being either functional pNETs, or large or symptomatic nonfunctioning pNETs. Conclusion: TSC-pNETs are rare and mostly nonfunctioning tumors with variable clinical behavior. Due to their uncertain malignant potential, we suggest that baseline pancreatic imaging should be incorporated into TSC surveillance, and we emphasize the need for heightened pNET surveillance and updated management recommendations.Keywords
This publication has 65 references indexed in Scilit:
- European Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and AdolescentsPediatric Blood & Cancer, 2026
- Tuberous sclerosis complex mutations in patients with pancreatic neuroendocrine tumors. Observations on phenotypic and treatment-related associationsVirchows Archiv, 2023
- Tuberous sclerosis complex‐associated nonfunctional pancreatic neuroendocrine tumors: Management and surgical outcomesAmerican Journal of Medical Genetics Part A, 2022
- Overview of the 2022 WHO Classification of Neuroendocrine NeoplasmsEndocrine Pathology, 2022
- The metformin in tuberous sclerosis (MiTS) study: A randomised double-blind placebo-controlled trialeClinicalMedicine, 2021
- Neuroendocrine Neoplasia Management2021
- Frequent falls and confusion: recurrent hypoglycemia in a patient with tuberous sclerosis complexClinical Case Reports, 2018
- Pancreatic neuroendocrine tumor in a patient with a TSC1 variant: case report and review of the literatureFamilial Cancer, 2017
- Expanding the Spectrum of Colonic Manifestations in Tuberous Sclerosis: L-Cell Neuroendocrine Tumor Arising in the Background of Rectal PEComaEndocrine Pathology, 2017
- Pancreatic tumors in children and young adults with tuberous sclerosis complexPediatric Radiology, 2016